Sumitomo Dainippon Pharma Aktie
| 6,78EUR | -0,20EUR | -2,81% |
WKN: 858257 / ISIN: JP3495000006
Personal
| 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 6 987 | 6 250 | 4 980 | 3 832 | 3 123 |
| Umsatz pro Mitarbeiter in Mio. EUR | 80,15 | 88,89 | 63,16 | 104,08 | 145,15 |
Bilanz (in Mio. JPY) - Aktiva
| 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 499 521 | 381 860 | 269 569 | 253 168 | 279 252 |
| Summe Anlagevermögen | 808 486 | 752 882 | 637 937 | 489 436 | 525 319 |
| Summe Aktiva | 1 308 007 | 1 134 742 | 907 506 | 742 604 | 804 571 |
Bilanz (in Mio. JPY) - Passiva
| 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 634 438 | 727 960 | 751 370 | 573 125 | 512 104 |
| Summe Eigenkapital | 673 569 | 406 782 | 156 136 | 169 479 | 292 467 |
| Summe Passiva | 1 308 007 | 1 134 742 | 907 506 | 742 604 | 804 571 |
Adresse
| 2-6-8 Dosho-machi, 541-0045 Osaka | |
| Telefon | +81 (6) 6203-5708 |
| Internet | https://www.sumitomo-pharma.co.jp |
Management
|
Hiroshi Niinuma
Director |
|
Hisayoshi Kashima
Director |
|
Katsuhiko Nishida
Executive Officer & General Manager-Sales |
|
Koichi Kozuki
Head-Business Development Promotions |
|
Koji Fujimoto
Independent Outside Director |
|
Mayumi Mochizuki
Independent Outside Director |
|
Minoru Usui
Independent Outside Director |
|
Mizuno Eihiro
Executive Officer, Head-Legal & Compliance |
|
Motoyuki Sakai
Representative Director & EVP-Communications |
|
Shunji Kobayashi
Executive Officer & Head-Human Resources |
|
Taishiro Michimori
Independent Outside Director |
|
Toru Kimura
President & Representative Director |
|
Tsutomu Nakagawa
Director & Managing Executive Officer |
|
Wakemi Yu
Executive Officer & Head-Accounting |
|
Yoshio Iteya
Independent Outside Director |
|
Yumi Sato
Head-Research & Development |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.